Persistence of Staphylococcus aureus colonization among individuals with immune-mediated inflammatory diseases treated with TNF-  inhibitor therapy

Varley, Cara D.; Deodhar, Atul; Ehst, Benjamin D.; Bakke, Antony C.; Blauvelt, Andrew; Vega, Robert; Yamashita, Shellie; Winthrop, Kevin

doi:10.1093/rheumatology/ket351

Cited by 21 publications

(15 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…JAK/STAT inhibitors have promising efficacy in EAE models as they are able to decrease clinical score severity and associated M1 inflammatory responses (Liu et al, 2014). Whether through biological or small synthetic molecules, one important caveat with globally blocking components of the M1 response is that it could lead to decreased host responses to pathogens and greatly increase risk for infection (Kwon et al, 2014, Varley et al, 2014). …”

Section: Therapeutic Manipulation Of M1 and M2 Responses In Pdmentioning

confidence: 99%

M1 and M2 immune activation in Parkinson’s Disease: Foe and ally?

2015

View full text Add to dashboard Cite

Parkinson Disease (PD) is a chronic and progressive neurodegenerative disorder of unknown etiology. Autopsy findings, genetics, retrospective studies, and molecular imaging all suggest a role for inflammation in the neurodegenerative process. However, relatively little is understood about the causes and implications of neuroinflammation in PD. Understanding how inflammation arises in PD, in particular the activation state of cells of the innate immune system, may provide an exciting opportunity for novel neuroprotective therapeutics. We analyze the evidence of immune system involvement in PD susceptibility, specifically in the context of M1 and M2 activation states. Tracking and modulating these activation states may provide new insights into both PD etiology and therapeutic strategies.

show abstract

Section: Therapeutic Manipulation Of M1 and M2 Responses In Pdmentioning

confidence: 99%

M1 and M2 immune activation in Parkinson’s Disease: Foe and ally?

2015

View full text Add to dashboard Cite

show abstract

“…Interestingly, patients who are already colonized by S . aureus are more likely to remain colonized after anti-TNF therapy than patients who are not on biologics [44]. It seems that anti-TNF treatment slightly reinforces S .…”

Section: Discussionmentioning

confidence: 99%

Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice

Wang

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

BackgroundRA patients being treated with biologics are known to have an increased risk of infections. We recently demonstrated that both CTLA4 Ig and anti-TNF treatment aggravate systemic Staphylococcus aureus (S. aureus) infection in mice, but with distinct clinical manifestations. However, the effects of CTLA4 Ig and anti-TNF treatments on a local S. aureus infection (e.g., skin infection) might differ from their effects on a systemic infection.AimsThe aim of this study was to examine the differential effects of anti-TNF versus CTLA4 Ig treatment on S. aureus skin infections in mice.MethodAbatacept (CTLA4 Ig), etanercept (anti-TNF treatment) or PBS was given to NMRI mice subcutaneously inoculated with S. aureus strain SH1000. The clinical signs of dermatitis, along with histopathological changes due to skin infection, were compared between the groups.ResultsBoth CTLA4 Ig and anti-TNF treatment resulted in less severe skin infections and smaller post-infectious hyperpigmentation compared with controls. Consistent with the clinical signs of dermatitis, smaller lesion size, more epithelial hyperplasia and more granulation were found in skin biopsies from mice receiving anti-TNF compared with PBS controls. However, both CTLA4 Ig and anti-TNF therapy tended to prolong the healing time, although this finding was not statistically significant. Serum MCP-1 levels were elevated in the anti-TNF group relative to the CTLA4 Ig and PBS groups, whereas IL-6 levels were higher in PBS controls than in the other two groups. Both anti-TNF and CTLA4 Ig treatments tended to down-regulate the necrosis/apoptosis ratio in the locally infected skin tissue. Importantly, no tangible difference was found in the bacterial burden among groups.ConclusionBoth CTLA4 Ig and anti-TNF therapies attenuate disease severity but may prolong the healing time required for S. aureus skin infections. Neither treatment has an impact on bacterial clearance in skin tissues.

show abstract

“…Recent literature suggests that TNF inhibition may be associated with persistent Staphylococcus aureus carriage, 10 which may account for the fissuring and crusting morphology of the patient rashes. However, only 3 lesions were cultured, and of those, only one grew out S aureus .…”

Section: Discussionmentioning

confidence: 99%

Persistence of Staphylococcus aureus colonization among individuals with immune-mediated inflammatory diseases treated with TNF- inhibitor therapy

Abstract: Patients with psoriasis are more likely to be colonized with S. aureus than patients with RA. Patients who are colonized with S. aureus are more likely to remain colonized if exposed to TNF-α inhibitors.

Cited by 21 publications

References 18 publications

M1 and M2 immune activation in Parkinson’s Disease: Foe and ally?

M1 and M2 immune activation in Parkinson’s Disease: Foe and ally?

Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice

Novel posterior auricular cutaneous reaction after anti–TNF-α infusion in young women with Crohn's disease

Contact Info

Product

Resources

About